Notably, we observed that both LC3B‐II and SQSTM1/p62 protein levels were lowered by polydatin treatment in our mouse NASH model, suggesting polydatin could rectify the impaired lysosomal degradation function (Figure 3A). This evidence concerns the gene SQSTM1 and metabolic dysfunction-associated steatohepatitis.